Journey Medical Operating Income Over Time
| DERM Stock | USD 8.33 0.39 4.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Journey Medical Performance and Journey Medical Correlation. Will Biotechnology sector continue expanding? Could Journey diversify its offerings? Factors like these will boost the valuation of Journey Medical. Projected growth potential of Journey fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Journey Medical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.35) | Revenue Per Share | Quarterly Revenue Growth 0.205 | Return On Assets | Return On Equity |
Understanding Journey Medical Corp requires distinguishing between market price and book value, where the latter reflects Journey's accounting equity. The concept of intrinsic value—what Journey Medical's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Journey Medical's price substantially above or below its fundamental value.
It's important to distinguish between Journey Medical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Journey Medical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Journey Medical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Journey Medical Corp and related stocks such as OrganiGram Holdings, Cartesian Therapeutics, and China SXT Pharmaceuticals Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OGI | (140.2 K) | (140.2 K) | (375.2 K) | (1.6 M) | (1.2 M) | 1.2 M | (11.1 M) | 36.4 M | 5.5 M | (145.5 M) | (91.8 M) | (43.2 M) | (242.7 M) | (35.7 M) | (63.4 M) | (57.1 M) | (59.9 M) |
| RNAC | (15.4 M) | (15.4 M) | (15.4 M) | (15.4 M) | (15.4 M) | (25.3 M) | (34.7 M) | (63.8 M) | (65 M) | (52.5 M) | (56.8 M) | (4.6 M) | 14.5 M | (86.4 M) | (43.9 M) | (39.5 M) | (41.5 M) |
| SXTC | 209.1 K | 209.1 K | 209.1 K | 209.1 K | 209.1 K | 209.1 K | 1.6 M | 1.6 M | 1.8 M | 4.3 M | (2.2 M) | (5.2 M) | (5.6 M) | (2.5 M) | (2.7 M) | (2.4 M) | (2.3 M) |
| FENC | (1.6 M) | (3.4 M) | (3.6 M) | (1.9 M) | (2.9 M) | (1.9 M) | (2.9 M) | (7 M) | (10.4 M) | (13 M) | (17.9 M) | (17.1 M) | (21.7 M) | (12.8 M) | 2.6 M | 2.3 M | 2.4 M |
| HSDT | (8.5 M) | (8.5 M) | (8.5 M) | (1.1 M) | (9.8 M) | (9.3 M) | (9.3 M) | (22.9 M) | (26.7 M) | (24 M) | (14.1 M) | (18.1 M) | (15.5 M) | (12.4 M) | (13.9 M) | (12.5 M) | (13.1 M) |
| OBIO | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (21.8 M) | (32.7 M) | (51.5 M) | (64.3 M) | (57.9 M) | (60.8 M) |
| IVA | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (13.5 M) | (15.5 M) | (13 M) | (20.9 M) | (33.3 M) | (30.3 M) | (29.7 M) | (52.1 M) | (57.1 M) | (102.7 M) | (97.6 M) | (87.8 M) | (83.4 M) |
| OSUR | (2.7 M) | (9.4 M) | (16.3 M) | (12.2 M) | (4.8 M) | 8.1 M | 20.3 M | 40.2 M | 28.4 M | 18.6 M | (5.2 M) | (10.2 M) | (22.2 M) | 32.7 M | (28.2 M) | (32.5 M) | (30.9 M) |
| MDWD | (4.3 M) | (4.3 M) | (2.7 M) | (7.6 M) | (21.4 M) | (21.2 M) | (20.2 M) | (13.7 M) | (10.7 M) | 5.7 M | (8.8 M) | (11.2 M) | (7.7 M) | (15.5 M) | (19.4 M) | (17.4 M) | (18.3 M) |
| NYXH | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (8.4 M) | (8.5 M) | (11.2 M) | (26.2 M) | (32.5 M) | (45.1 M) | (58.8 M) | (52.9 M) | (50.3 M) |
Journey Medical Corp and related stocks such as OrganiGram Holdings, Cartesian Therapeutics, and China SXT Pharmaceuticals Operating Income description
Operating Income is the amount of profit realized from Journey Medical Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Journey Medical Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Journey Medical Corp | DERM |
| Classification | Drugs |
| Business Address | 9237 East Via |
| Exchange | NASDAQ Exchange |
USD 8.33
Check out Journey Medical Performance and Journey Medical Correlation. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Journey Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.